apolipoprotein A-1, high-density lipoprotein, aspartate aminotransferase, creatine, and urine pH were statistically associated with PV. PSA, fat mass, apolipoprotein A-1, creatine, and urine pH were significant predictive factors for both PV and TV. For men aged >40 years without prostate cancer history and treatment for BPH/LUTS, TZI (Hazzad ration (HR) ¼1.02, p ¼ 0.001), total IPSS (HR ¼ 1.04, p ¼ 0.004) and alpha-fetoprotein (AFP) (HR ¼ 0.86, p¼0.040) were significant risk factors for the development of BPH/LUTS within 5 years.
INTRODUCTION AND OBJECTIVES: Discovery of serum biomarkers for benign prostatic hyperplasia (BPH) is strongly pursued by the MTOPSProstatic Samples Analysis (MPSA) Consortium and other groups in order to discriminate BPH-related pathologies, identify risk of progressive disease; and personalized management of BPH-related LUTS. Compared to serum, urine collected non-invasively by the patient himself has obvious advantages as a suitable matrix for BPH biomarker discovery. Besides, proximity to prostate can permit selective contribution of BPH related proteins into urine. Here, we compared the distribution of prostatic inflammation mediators in the two biofluids obtained from a rat model. METHODS: Non-bacterial prostatic inflammation was induced by intraprostatic injection of formalin (50mL) or saline (sham) in three month-old male Sprague-Dawley rats (n¼4 in each group). 12 hour night time urination pattern were noted in metabolic cage a day before injection and 7 days later. Urine and serum collected on 7th day was frozen prior to simultaneous multiplex analysis of 27 proteins using a MILLIPLEX MAP Rat Cytokine/Chemokine Panel kit (Millipore, Billerica, MA) .
RESULTS: Attached figure demonstrates that EGF, GM-CSF, IFN-g, IL-1b, IL-10, IL-18 and eotaxin were abundant in urine, while undetectable in serum. Paired analysis of urine and serum levels from sham group against the levels of prostatitis group referred to as urine-P and serum-P, respectively found that VEGF, IL-1a, IL-4, CXCL-10 and CX3CL1 were elevated in urine-P, whereas IL-5 and CCL5 were elevated in serum-P (*p<0.05). Levels of CXCL-5, IL-12p70, CCL2, CCL3, G-CSF, TNF-a and Leptin were comparable in the biofluids of both groups. Significantly decreased levels of CXCL-10 and CX3CL-1 in serum of prostatitis group (#p<0.05) is linked to their commensurate increase in urine-P, which also showed slightly elevated IL-6, IL-13 and IL-17A.
CONCLUSIONS: Majority of the mediators driving prostatic inflammation were abundant in urine, while several of the mediators were undetectable in serum. Whether this discordance in the biofluids is linked to the increased proteolysis of chemokines in serum or to the exclusive secretion of chemokines from prostate into urine needs to be studied. Urine is a reliable matrix for the discovery of potential noninvasive biomarkers for the routine clinical management of BPH.
Source of Funding: NIDDK U54 DK112079

MP13-20 THROMBOSPONDIN-1 HAS A POSSIBILITY OF BIOMARKER PREDICTING THE PROGRESSION OF BENIGN PROSTATIC HYPERPLASIA.
Takashi Hamakawa*, Shoichi Sasaki, Yuya Ota, Naoko Unno, Rika Banno, Masa Takada, Yasue Kubota, Kenjiro Kohri, Takahiro Yasui, Nagoya, Japan INTRODUCTION AND OBJECTIVES: Many factors affect the pathogenesis of benign prostatic hyperplasia (BPH). Previously, we reported that interleukin-18 (IL-18) may promote stromal hyperplasia in the prostate by inducing production of thrombospondin-1 (TSP-1), as known a regulator of angiogenesis and an activator of latent transforming growth factor beta, using BPH rat model and human cultured prostatic cells. Therefore, in this study, we aimed to determine the expression levels of IL-18 and TSP-1 in human prostate tissue and assess the roles of these expressions as biomarkers to diagnose the progression of BPH.
METHODS: Study 1: We enrolled 28 patients without malignancy who underwent transperineal prostate biopsy at our institution. We obtained prostate tissues from the transitional zone and used these samples for total RNA extraction and cDNA preparation. The expression levels of IL-18 and TSP-1 mRNAs were evaluated by quantitative real-time reverse transcription polymerase chain reaction. We evaluated the correlation between mRNA expression levels and age, total prostate volume (TPV), transitional zone volume (TZV), transitional zone index (TZI), and serum PSA levels using Pearson's productmoment correlation coefficient. Study 2: Samples from 11 of the patients in Study 1 were used to measure the volume of the prostate at biopsy and at a given point in time after biopsy. We evaluated the correlation between the increase in prostate volume per month and mRNA expression.
RESULTS: Study 1: There were no correlations among age, serum PSA levels, and mRNA expression. TSP-1 expression was positively correlated with TPV (r ¼ 0.696) and TZV (r ¼ 0.629). Study 2: The mean observation period was 23.9 AE 13.4 months, and the mean increase in prostate volume was 10.4 AE 12.3 ml. There was a strong positive correlation between the increase in volume per month and TSP-1 expression (r [ 0.663).
CONCLUSIONS: TSP-1 expression was positively correlated with prostate volume and the increase in prostate volume per month. This result suggested that TSP-1 might be a potential biomarker for predicting the development of BPH.
Source of Funding: none Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e161
